Format

Send to

Choose Destination
JACC Cardiovasc Interv. 2017 Aug 28;10(16):1682-1690. doi: 10.1016/j.jcin.2017.04.041. Epub 2017 Aug 2.

The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon.

Author information

1
Regiomed Vascular Center Sonneberg, Sonneberg, Germany; Jena University Hospital, Jena, Germany. Electronic address: marcus.thieme@medinos-kliniken.de.
2
Diakoniewerk Munchen, München, Germany.
3
Kliniken Nordoberpfalz AG, Weiden, Germany.
4
University Hospital of Patras, Patras, Greece.
5
Arberlandklinik Viechtach, Viechtach, Germany.
6
Klinikum Arnsberg, Karolinen-Hospital Huesten, Arnsberg, Germany.

Abstract

OBJECTIVES:

The Global SFA Registry sought to assess safety, clinical benefit, and outcomes of the Lutonix 035 drug-coated balloon (DCB) in a heterogeneous, real-world patient population at 12 and 24 months.

BACKGROUND:

Numerous clinical studies have evaluated the use of angioplasty for revascularization of femoropopliteal arteries in peripheral arterial disease with restenosis rates of 40% to 60% at 6 to 12 months. Data from recent studies document decreased restenosis rates and improvement in patency in patients receiving angioplasty of femoropopliteal arteries with DCBs.

METHODS:

The multicenter, prospective study enrolled 691 patients in 38 centers from 10 countries treated with the Lutonix 035 DCB in femoropopliteal lesions. The primary safety endpoint was freedom from a composite of target vessel restenosis, major index limb amputation, and device- or procedure-related death at 30 days. The primary effectiveness endpoint was freedom from target lesion restenosis at 12 months. Secondary endpoints were acute device and procedural success and clinically assessed primary patency.

RESULTS:

Freedom at 30 days from the composite safety endpoint was 99.4%. Freedom from target lesion restenosis was 93.4%/89.3% for the overall population, 93.2%/88.2% for long lesions up to 500 mm, and 90.7%/84.6% for in-stent restenosis at 12/24 months. Clinically assessed primary patency by Kaplan-Meier estimates was 85.4%/75.6% at 12/24 months. More than 76% of patients showed improvement of at least 1 Rutherford category.

CONCLUSIONS:

The Global SFA Registry 24-month outcomes confirm the Lutonix 035 DCB is a safe and effective long-term treatment option in real-world patients with peripheral arterial disease with superficial femoral artery lesions, also in long lesions and in-stent restenosis. (Lutonix Global SFA Registry; NCT01864278).

KEYWORDS:

amputation; angioplasty; drug-coated balloon; paclitaxel; peripheral artery disease; restenosis

PMID:
28780030
DOI:
10.1016/j.jcin.2017.04.041
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center